...

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France

【24h】

P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France

机译：法国非小细胞肺癌（NSCLC）中与癌症疗法相关的不良事件（AE）的成本P1.06-044

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 》 |2017年第1期| 共1页
作者
Christos Chouaid; Delphine Loirat; Chloé Godard; Emilie Clay; Aurélie Millier; Laurie Lévy-Bachelot; Eric Angevin;
展开▼
作者单位

Centre Hospitalier Intercommunal Créteil;

Curie Institute;

Msd;

Creativ-Ceutical;

Creativ-Ceutical;

Msd;

Départment Innovations Thérapeutiques Et Essais Précoces (Ditep) Gustave Roussy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France [J] . Christos Chouaid, Delphine Loirat, Chloé Godard, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017 ,第1期

机译：法国非小细胞肺癌（NSCLC）中与癌症疗法相关的不良事件（AE）的成本P1.06-044
2. P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France [J] . Christos Chouaid, Delphine Loirat, Chloé Godard, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017 ,第1期

机译：法国非小细胞肺癌（NSCLC）中与癌症疗法相关的不良事件（AE）的成本P1.06-044
3. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. [J] . Banz K, Bischoff H, Brunner M, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2011 ,第3期

机译：在德国，法国，意大利和西班牙比较晚期厄立替尼或培美曲塞维持治疗对3/4级不良事件的治疗费用。
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. 4HPR-X radiation mechanisms of interactions in non-small cell lung cancer (NSCLC) cells in vitro. [D] . Nasca, Melita Maria. 2002

机译：4HPR-X辐射在非小细胞肺癌（NSCLC）细胞中相互作用的体外机制。
6. Cost analysis of adverse events associated with non-small cell lung cancer management in France [O] . Christos Chouaid, Delphine Loirat, Emilie Clay, 2017

机译：法国非小细胞肺癌管理相关不良事件的成本分析
7. PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE [O] . Chouaid C, Vergnenegre A, Brunner M, 2009

机译：PCN43在法国治疗晚期非小细胞肺癌患者中与贝伐珠单抗加化学疗法对西妥昔单抗加西铂/长春瑞滨治疗一线治疗相关的3/4级不良事件的成本

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号